Finland
Maculaser Ltd, based in Finland, is an innovative medical technology company focused on restoring retinal health through groundbreaking treatments for common retinal diseases, such as dry Age-related Macular Degeneration. Established in 2020, Maculaser has carved a niche by developing a technology that offers precise temperature control of the macula, making non-damaging laser treatments viable for conditions previously considered untreatable.
With their proprietary technique, Maculaser not only promises to revolutionize the treatment process but also addresses a pressing medical challenge linked to retinal diseases, a market associated with over USD 400B in direct healthcare costs globally. The potential to improve millions of lives by preventing vision loss makes this innovation particularly compelling.
The company secured a €1.20M seed investment in February 2021 from notable investors like Innovestor and Jaakko Ollila. This financial support underscores the confidence investors have in Maculaser's vision and technological breakthroughs.
